SELLAS Life Sciences Appoints New Director, Director Departs
Ticker: SLS · Form: 8-K · Filed: Jan 16, 2025 · CIK: 1390478
| Field | Detail |
|---|---|
| Company | Sellas Life Sciences Group, Inc. (SLS) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, management-changes
TL;DR
SELLAS board shakeup: Marfione out, Boyer in as director.
AI Summary
On January 10, 2025, SELLAS Life Sciences Group, Inc. announced changes to its Board of Directors. Dr. Anthony S. Marfione, Jr. resigned from his position as a Class II Director, effective January 10, 2025. Concurrently, the company appointed Dr. Jeffrey S. Boyer as a new Class II Director, also effective January 10, 2025.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future decision-making.
Risk Assessment
Risk Level: low — This filing reports routine board changes and does not involve significant financial transactions or operational shifts.
Key Players & Entities
- SELLAS Life Sciences Group, Inc. (company) — Registrant
- Dr. Anthony S. Marfione, Jr. (person) — Resigning Class II Director
- Dr. Jeffrey S. Boyer (person) — Appointed Class II Director
- January 10, 2025 (date) — Effective date of changes
FAQ
Who resigned from the Board of Directors?
Dr. Anthony S. Marfione, Jr. resigned from his position as a Class II Director.
When was the resignation effective?
The resignation was effective on January 10, 2025.
Who was appointed to the Board of Directors?
Dr. Jeffrey S. Boyer was appointed as a new Class II Director.
When was the new director appointed?
Dr. Jeffrey S. Boyer's appointment was effective on January 10, 2025.
What class of director was affected by these changes?
Both the departing and newly appointed directors were Class II Directors.
Filing Stats: 604 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2025-01-16 16:11:13
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SLS The Nasdaq St
Filing Documents
- tm253479d1_8k.htm (8-K) — 24KB
- 0001104659-25-004107.txt ( ) — 194KB
- sls-20250110.xsd (EX-101.SCH) — 3KB
- sls-20250110_lab.xml (EX-101.LAB) — 33KB
- sls-20250110_pre.xml (EX-101.PRE) — 22KB
- tm253479d1_8k_htm.xml (XML) — 4KB
02
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 10, 2025, the Board of Directors (the " Board ") of SELLAS Life Sciences Group, Inc. (the " Company ") approved an amendment to the Change in Control Severance Agreement, dated December 14, 2021 (the " Cicic Severance Agreement "), by and between the Company and Dragan Cicic, Senior Vice President and Chief Development Officer of the Company, to provide for severance of 15 months of the applicable then-current base salary upon a termination in connection with a change of control. Additionally, on January 10, 2025, the Board approved an amendment to the Change in Control Severance Agreement, dated December 14, 2021 (the " Burns Severance Agreement "), by and between the Company and John Burns, Senior Vice President and Chief Financial Officer of the Company, to provide for severance of 15 months of the applicable then-current base salary upon a termination in connection with a change of control. All other provisions in the Cicic Severance Agreement and Burns Severance Agreement, respectively, remain the same. The foregoing descriptions of the amendments to the Cicic Severance Agreement and Burns Severance Agreement are not complete and are qualified in their entirety by reference to the full text of the amendments to the Cicic Severance Agreement and Burns Severance Agreement, copies of which will be filed with the Company's next periodic report to be filed with the U.S. Securities and Exchange Commission.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SELLAS Life Sciences Group, Inc. Date: January 16, 2025 By: /s/ John T. Burns Name: John T. Burns Title: Senior Vice President, Chief Financial Officer